Results 81 to 90 of about 5,546 (214)
Clinical Case Reports, Volume 13, Issue 3, March 2025.ABSTRACT Insulinoma is a rare functional pancreatic neuroendocrine tumor with an annual prevalence of 0.5–5 cases per million. It is characterized by excessive insulin secretion, leading to recurrent hypoglycemia, often diagnosed through Whipple's triad: hypoglycemic symptoms, documented low plasma glucose, and symptom resolution after glucose ...
Ankit Shrestha +6 more
wiley +1 more source
Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors [PDF]
, 2018 Background. Neuroendocrine tumors (NETs) are characterized by having behavior and prognosis that depend upon tumor histology, primary site, staging, and proliferative index.
Baldelli, Roberto +8 more
core +1 more source
Clinical Endocrinology, Volume 102, Issue 3, Page 344-354, March 2025.ABSTRACT The management of hypoglycaemia is pivotal in the care of patients with insulinoma. Blood glucose monitoring and regulation needs careful attention pre‐ and peri‐operatively for patients undergoing surgical resection and as part of the long‐term management for patients with inoperable or metastatic disease.
Sophie Howarth +3 more
wiley +1 more source
Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
Endocrine Connections, 2019 Purpose: Little data are available regarding the safety and efficacy of s witching to Pasireotide-LAR monotherapy in acromegaly patients with partial resistance to first-generation somatostatin agonists (1gSRL) who require combination treatment with ...
Hélène Lasolle +5 more
doaj +1 more source
Grading and staging for pituitary neuroendocrine tumors
Brain Pathology, Volume 35, Issue 1, January 2025.Abstract Pituitary adenoma/pituitary neuroendocrine tumors (PitNETs) are the second most common primary intracranial tumor and the most frequent neuroendocrine tumors/neoplasms of the human body. Thus, they are one of the most frequent diagnoses in neuropathologist's practise.
Chiara Villa +6 more
wiley +1 more source
New cross-roads for second line medical therapy in acromegaly [PDF]
Archives of the Balkan Medical Union, 2018 Acromegaly is a complex disorder caused by growth hormone excess mostly due to a pituitary adenoma. Surgery represents the first option but rate of long time success is almost 50% thus the patients need other therapies.
Adina Ghemigian +5 more
doaj
Clinical Pharmacology: Advances and Applications, 2021 Alexia Rouland,1 Benjamin Bouillet,1,2 Pauline Legris,1 Isabelle Simoneau,2 Jean-Michel Petit,1,2 Bruno Vergès1,2 1Endocrinology Diabetics and Metabolic Disorders Department, Dijon University Hospital, Dijon, France; 2French National Health and ...
Rouland A +5 more
doaj
BMC Endocrine Disorders, 2018 Background The approach to acromegalic patients with persistent acromegaly after surgery and inadequate response to first-generation somatostatin receptor ligands (SRLs) should be strictly tailored.
A. Ciresi +3 more
doaj +1 more source
Brain Pathology, Volume 35, Issue 1, January 2025.This article reviews the major biological characteristics of somatostatin receptors (SST2 and SST5) in anterior pituitary tumors, and the immunohistochemical evaluation of their expression as predictors of response to pharmacological therapy with SST ligands.
Laura Botelho +5 more
wiley +1 more source
A szomatosztatinanalógok hatékonysága a neuroendokrin daganatok kezelésében az új klinikai vizsgálatok tükrében [PDF]
, 2015 Due to their inhibitory effects on hormone secretion, somatostatin analogues are of pivotal importance in the symptomatic treatment of hormone-secreting neuroendocrine tumours.
Igaz, Péter
core +1 more source